Drug Panel Asks Protection For Volunteers

LONDON—The U.K. Medicines Commission is calling for a clampdown on independent contractors who hire healthy volunteers to test experimental drugs, but the code may never be enacted. The drug regulation agency, headed by Rosalinde Hurley of London University, wants a register of contractors, limits on payments to experimental subjects, and guarantees that the volunteers will get full medical backup and nofault compensation if they suffer side effects. Its proposal is prompted by concern

Written byAndrew Veitch
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

LONDON—The U.K. Medicines Commission is calling for a clampdown on independent contractors who hire healthy volunteers to test experimental drugs, but the code may never be enacted.

The drug regulation agency, headed by Rosalinde Hurley of London University, wants a register of contractors, limits on payments to experimental subjects, and guarantees that the volunteers will get full medical backup and nofault compensation if they suffer side effects. Its proposal is prompted by concern over the increasing numbers of independent contractors setting up shop to test experimental drugs for pharmaceutical companies.

Ministers asked the commission three years ago to produce safeguards following an outcry over the death of two student volunteers.

Hurley’s team produced its report one year ago. Ministers delayed publication until September, and no substantial government reply is expected until early next year.

More than 8,000 people volunteer for Phase 1 trials of potential new products every year in ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies